AIO Studien gGmbH

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase <scp>II</scp> trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

Ralf‐Dieter Hofheinz, S. Hegewisch-Becker, Volker Kunzmann et al. · International Journal of Cancer · 2021 · 95 citations · Full text

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Frank Griesinger, Wilfried Eberhardt, Arnd Nusch et al. · Lung Cancer · 2020 · 83 citations · Full text

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Martin Sebastian, Wilfried Eberhardt, Petra Hoffknecht et al. · Lung Cancer · 2021 · 75 citations · Full text

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated <i>ERBB2</i>-Positive Esophagogastric Adenocarcinoma

Alexander Stein, Lisa Paschold, Joseph Tintelnot et al. · JAMA Oncology · 2022 · 54 citations · Full text

Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial

Volker Kunzmann, Hana Algül, Eray Goekkurt et al. · Annals of Oncology · 2019 · 37 citations · Full text

Pancreatic Cancer, Conversion Rate, Gastrointestinal Oncology +8